Celgene/Novartis dexmethylphenidate
Executive Summary
Approval of dexmethylphenidate, a single-isomer version of Novartis' attention deficit hyperactivity disorder drug Ritalin, is expected within six to eight weeks pending labeling negotiations, Celgene said Aug. 21 following "approvable" letter from FDA. Celgene and Novartis, which will market the product, have proposed the trade name Ritadex (formerly Ritalin-D). Novartis filed an NDA for a once-daily methylphenidate modified-release capsule Ritalin LA on Nov. 29, 2000 and is predicting a fourth quarter approval
You may also be interested in...
Novartis Focalin Price Similar To Ritalin; ADHD Drug Clears FDA Nov. 13
Novartis' Focalin will be priced similarly to its parent compound Ritalin, the company said following the Nov. 13 approval of the attention deficit hyperactivity disorder drug
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011